Insulin human - Biologic Drug Details

Summary for insulin human

Tradenames:	5
High Confidence Patents:	10
Applicants:	4
BLAs:	4
Suppliers: see list	5
Recent Clinical Trials:	See clinical trials for insulin human

Recent Clinical Trials for insulin human

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Eurofarma Laboratorios S.A.	PHASE3
Wake Forest University Health Sciences	PHASE3
University of Wisconsin, Madison	EARLY_PHASE1

See all insulin human clinical trials

Pharmacology for insulin human

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin human Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin human Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938		2014-10-14	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938		2014-03-24	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938		2014-09-26	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938		2017-07-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin human Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2033-06-12	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2036-05-19	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2035-05-15	Patent claims search
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780		2035-04-14	Patent claims search

International Patents for insulin human

Country	Patent Number	Estimated Expiration
Portugal	2379100
South Korea	100486373
Poland	337218
South Korea	20140015119

Market Dynamics and Financial Trajectory for the Biologic Drug: Insulin Human

Last updated: July 29, 2025

---

Introduction

Insulin human, a recombinant form of insulin identical to endogenous human insulin produced via recombinant DNA technology, remains foundational in managing diabetes mellitus. Its long-standing clinical efficacy and safety profile have established its critical role in diabetes care. As a biologic, insulin human's market landscape is shaped by regulatory environments, technological advancements, competitive dynamics, and the burgeoning global diabetes epidemic.

This analysis explores the evolving market dynamics and the financial trajectory of insulin human, focusing on factors influencing supply, demand, pricing, innovation, and strategic positioning within the broader diabetes therapeutics market.

---

Market Overview: Insulin Human in the Global Context

Insulin human maintains a dominant position among insulin formulations, historically supplied through various recombinant DNA techniques, such as Escherichia coli or yeast fermentation. According to PharmaIntelligence, global insulin sales exceeded $25 billion in 2022, with human insulin accounting for a significant share — estimated at approximately 40-45% — owing to its affordability and longstanding efficacy [[1]].

The widespread prevalence of diabetes, projected to rise from 463 million in 2019 to 700 million by 2045 globally, underpins sustained demand [[2]]. The International Diabetes Federation (IDF) reports a persistent need for cost-effective, accessible insulin therapies, especially in low- and middle-income countries, fueling the continued relevance of insulin human.

---

Market Dynamics Influencing Insulin Human

1. Technological Stability Versus Innovation

While insulin analogs (e.g., aspart, lispro, glargine) offer pharmacokinetic enhancements, insulin human remains the cost-effective choice for many markets due to lower production costs and existing manufacturing infrastructure [[3]]. However, the innovation landscape is dynamic; whether new biosimilar insulin formulations or alternative delivery systems will challenge the standing of insulin human is a crucial consideration.

2. Patent Expirations and Biosimilar Entry

Major insulin producers like Eli Lilly, Novo Nordisk, and Sanofi have patente expirations for certain insulin compounds, enabling the emergence of biosimilar insulin formulations. These biosimilars, notably insulin human, aim to capture price-sensitive markets by offering equivalent efficacy at lower costs. The entry of biosimilars is expected to exert downward pressure on insulin prices, impacting revenue streams of original manufacturers [[4]].

3. Regulatory and Policy Factors

Global regulatory frameworks increasingly facilitate biosimilar approvals to promote access. The US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other agencies have established pathways for biosimilar insulin, accelerating market entry [[5]]. Conversely, pricing policies, reimbursement schemes, and government interventions in key markets—particularly in the US and Europe—can influence market growth trajectories.

4. Pricing and Reimbursement Landscape

The cost of insulin remains a contentious issue. Variations in reimbursement policies, especially in countries like the US, where pricing is predominantly market-driven, influence patient access and manufacturer profitability. Increased adoption of biosimilar insulin is expected to foster competitive pricing, but market fragmentation and regulatory hurdles may limit rapid price declines.

5. Shift Toward Digital and Delivery Innovations

Emerging delivery systems, including insulin pumps with integrated digital health platforms, may alter demand patterns. While insulin human’s traditional subcutaneous formulations face competition from next-generation analogs, the integration of insulin human with cost-effective delivery devices can sustain its market relevance, particularly in resource-limited settings.

---

Financial Trajectory and Investment Perspectives

1. Revenue Trends and Market Share

Historically, insulin sales have provided stable revenue streams for incumbent producers. Despite the introduction of biosimilars, insulin human's volumes are expected to remain robust, driven by high patient retention, established manufacturing, and expanding global access. However, revenue growth may plateau or decline modestly due to biosimilar competition and pricing pressures [[6]].

2. Impact of Biosimilars on Profitability

Biosimilar entry has the potential to erode margins for original manufacturers. According to IQVIA, biosimilar insulins are entering markets with discounts ranging from 20-40% compared to branded analogs, reducing premium pricing opportunities for insulin human formulations [[7]].

3. Cost of Goods and Manufacturing Efficiency

The manufacturing process of insulin human benefits from mature, scalable technology. Cost efficiencies gained through process optimization—such as enhanced fermentation and purification—are critical for sustaining profitability amidst declining market prices [[8]].

4. Investment in R&D and Lifecycle Management

Original developers invest in developing improved formulations, delivery devices, and combination products involving insulin human to extend lifecycle and capture new market segments. Such innovation preserves financial value and mitigates revenue erosion.

---

Geographic and Demographic Drivers

1. Emerging Markets as Growth Drivers

Low- and middle-income countries (LMICs) represent promising growth areas due to rising diabetes prevalence and affordability needs. The WHO estimates insulin access remains limited in numerous LMICs, presenting opportunities for differentiated pricing and local manufacturing [[9]]. Insulin human, with its cost advantage, is central to this segment.

2. Developed Markets: Evolving Competitive Landscape

In mature markets like the US and EU, insulin analogs dominate premium segments. Nonetheless, biosimilar insulin human formulations are gradually gaining acceptance, especially within subsidy and reimbursement environments seeking to contain costs. The financial impact on traditional insulin formulations will depend on policy, physician preferences, and patient acceptance.

---

Future Outlook and Market Opportunities

While insulin human shows signs of market maturation, opportunities persist in expanding access, especially via biosimilars and alternative delivery systems. Strategic partnerships, manufacturing optimization, and adoption of digital health solutions will shape profit trajectories.

Projected compound annual growth rates (CAGRs) for insulin market segments are expected to decline modestly—approximately 2-4% globally—over the next five years as biosimilar competition intensifies and innovation shifts focus. Nevertheless, total revenues for insulin human formulations will likely sustain due to volume-driven growth, especially in underserved markets.

---

Key Challenges and Risks

• Pricing pressures from biosimilars threaten revenue stability.
• Regulatory hurdles may delay biosimilar entry.
• Market fragmentation complicates global strategies.
• Patient acceptance of biosimilar insulin formulations remains variable.
• Technological shifts toward smart delivery devices and adjunct therapies might reconfigure demand dynamics.

---

Strategic Recommendations

• Invest in manufacturing efficiencies to sustain competitive pricing.
• Engage proactively with regulators to streamline biosimilar approval pathways.
• Expand access programs in LMICs, leveraging insulin human’s affordability.
• Partner with digital health firms to enhance patient adherence and outcomes.
• Monitor innovation trends (e.g., ultra-long-acting insulins, smart delivery) for potential integration or differentiation.

---

Key Takeaways

• Insulin human remains a cost-effective, globally relevant therapy amid rising diabetes prevalence.
• Biosimilar competition is likely to exert downward pressure on prices, impacting revenue growth.
• Market expansion in LMICs offers substantial growth potential due to unmet needs.
• Incumbent manufacturers should focus on manufacturing efficiency, regulatory agility, and patient-centered innovations.
• Overall, the financial outlook is stable but faces margin compression risks, necessitating strategic adaptation.

---

FAQs

1. How will biosimilar insulins impact the market for insulin human?
Biosimilars will increase price competition and market share for insulin human, particularly in cost-sensitive regions. This can reduce profit margins but also expand access, encouraging market growth through volume.

2. What factors could accelerate the adoption of insulin human in emerging markets?
Cost advantages, local manufacturing initiatives, supportive regulatory frameworks, and targeted access programs can propel adoption of insulin human in LMICs where affordability is critical.

3. Are there technological innovations that threaten insulin human’s market position?
Yes, advances in insulin analogs, ultra-long-acting formulations, smart delivery devices, and combination therapies could diminish insulin human’s market share unless manufacturers adapt.

4. How significant is the role of regulatory policies in shaping insulin human’s financial trajectory?
Regulatory policies greatly influence biosimilar approval timelines and reimbursement schemes, directly impacting market entry, pricing, and revenue potential.

5. What strategic moves should manufacturers consider to maximize profits from insulin human?
Manufacturers should optimize production costs, expand into underserved markets, develop value-added delivery systems, and invest in lifecycle management and biosimilar development to sustain profitability.

---

Sources

[1] PharmaIntelligence. "Global Insulin Market Analysis." 2022.
[2] International Diabetes Federation. "Diabetes Atlas," 9th Edition. 2019.
[3] Ziyadeh, F. N. et al. "Current and Future Use of Human Insulin in Diabetes Management." Diabetes Therapy. 2017.
[4] IQVIA. "Biosimilar Insulin Market Report," 2022.
[5] U.S. FDA, European Medicines Agency guidelines on biosimilar approvals, 2021.
[6] MarketWatch. "Insulin Market Trends," 2023.
[7] IQVIA. "Impact of Biosimilar Entry on Insulin Sales," 2022.
[8] Kuncir, G. et al. "Manufacturing Advances in Recombinant Human Insulin." Biotechnology Advances. 2021.
[9] WHO. "Global Access to Insulin," 2020.

---

This comprehensive review delivers a precise understanding of the current and future landscape of insulin human, empowering stakeholders to navigate and capitalize on market opportunities effectively.